tbuckley/cabot-search huggingface dataset:
AB1157 CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATIC DISEASES AFTER COVID-19 IN THE REPUBLIC OF TATARSTAN
Authors: S. Lapshina, N. Shamsutdinova, V. Mukhamadieva, R. Abdrakipov, E. Sukhorukova, A. Sagitova, A. Zakirova, L. Krasnova, D. Abdulganieva
Journal: Annals of the Rheumatic Diseases (2022)

Background The management of patients with rheumatic diseases (RD) who have undergone a new coronovirus infection (NCI) is an urgent and significant problem. Objectives To study the course of the NCI and its influence on the course of RD in the Republic of Tatarstan. Methods From June 2020 to January 2022, 159 cases of NCI with a confirmed SarsCoV2 PCR result and/or X-ray computed tomography (CT) of the lungs in patients with RD were analyzed. The study included 104 patients with RA, 36 patients with AS, 18 patients with PsA. RD activity before NCI was low in 56 (35.2%) patients, moderate in 91 (57.3%), and high in 12 (7.5%) patients. Distribution by gender: 113 (71.0%) females, 46 (28.9%) males, mean age 58 [46; 64]. 56 patients (49.5%) were hospitalized, the average age of those hospitalized was 61 [49; 67] year. The average duration of RD at the time of NCI was 11 [7; 16.75] years. The results of clinical and laboratory examinations were evaluated before and 1-3 months after the NCI. Results Manifestations of infection in patients with RD in terms of frequency and severity were comparable to the course of NCI in the population: intoxication with fever above 38C, respiratory symptoms, ageusia, anosmia, pneumonia. 27.1% (43) of patients had asymptomatic or mild course of COVID-19, 64.1% (102) had moderate course, 8.8% (14) of patients - severe NCI. Lung involvement was detected in 116 (72.9%) patients. Patients received NCI therapy according to national guidelines. The outcome of COVID-19 in 154 (96.9%) patients was recovery, in 5 (3.1%) patients it was fatal, 3 of them were on rituximab therapy. A total of 8 patients received rituximab. After undergoing NCI, 26 (16.4%) patients did not develop an increase in activity, in 76 (47.7%) patients RD corresponded to a moderate degree of activity. In 57 (35.9%) patients RD activity became high, 3 months after the NCI, a significant (p&lt;0.05) increase in the activity of the main RD was observed due to clinical and laboratory (C-reactive protein) parameters, which required intensification of antirheumatic therapy. Conclusion The prevalence and course of COVID-19 in patients with RD did not generally differ from those in the population. The most unfavorable course of NCI in terms of life prognosis was observed in patients receiving rituximab for underlying RD. The COVID-19 contributes to an increase in the activity of the main RD. Disclosure of Interests None declared
AB0735 Interstitial lung disease associated with systemic connective tissue diseases: dynamics of lung function after three years of follow-up
Authors: M. Starovoytova, O. Desinova, L. P. Ananyeva, R. Shayakhmetova, A. Khelkovskaia-Sergeeva, O. Koneva, L. Garzanova, O. Ovsyannikova
Journal: Annals of the Rheumatic Diseases (2022)

Background Interstitial lung disease (ILD) is one of the most common and severe manifestations of connective tissue diseases, such as systemic scleroderma (SSc), dermato- and polymyositis (DM/PM), mixed connective tissue disease (MCTD), etc. Objectives To compare the course and outcomes of ILD in SSD, MCTD and DM/PM, immunoinflammatory myopathies (IIM) after three years of follow-up. Methods The SSc group consisted of 82 patients, the IIM group – 61 patients, and the MCTD group – 20 patients. In all the studied groups, women predominated. The oldest patients were found in the IIM group, and the average age was 51±12.88 years. The duration of the disease varied from 0.5 to 18.5 years. A longer course of the disease was observed among patients with MCTD, the median was 10.6 (6.9; 18.5) years. When assessing the initial parameters of lung function tests, significantly lower values of FVC and DCL were recorded in the IIM group (on average, 82±21.5 and 51.1±16.2, respectively), and higher values in the MCTD group (95.4± 20 and 67.5±15). All patients took GCs, the highest doses were taken by patients with IIM. The great majority of patients received immunosuppressants, of which 100% of patients were in the MCTD group. Results Despite the fact that the indices of FVC and DСL in the SSc group were initially lower (on average 91.8±19.1 and 59.2±19.5, respectively) than in the MCTD group. The dynamics of Δ FVC over three years against the background of ongoing therapy was discordant: Δ FVC in the SSc group significantly increased [0.6 (-8; 4.9)], in the MCTD group, it decreased [-5.7 (-10.3; 10.9)]. The mean value of DCL over the follow-up period remained practically the same; the dynamics between the groups was also discordant: it slightly increased in patients with SSc [1.1 (-3.8; 4.6)] and decreased in patients with MCTD [-1.6 (-11.2; 12.6)]. FEV1 decreased in both SSD and MCTD groups, but the alterations were not significant. In the group of patients with IIM during the follow-up period, there was a significant increase in the mean values of Δ DCL, FVC and FEV1 [9.8 (4-16), 13.9 (3.2-28.5), 10.2 (2-26.8)]. Conclusion Therefore, due to the study, positive dynamics in lung function in patients with ILD was noticed in the IIM group, stabilization of the pathological process and the absence of progression in the SSc group were achieved, and, despite the initially higher values of FVC and DCL, negative dynamics was detected in the group of patients with MCTD. It is likely that the positive dynamics of lung function in patients with IIM is due not only to an improvement in the condition of the lungs, but also to an increase in muscle strength. A peculiarity of the group of patients with IIM is the high frequency of intake of rituximab in this group (40 patients). Disclosure of Interests None declared
AB0115 MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN PATIENTS WITH PSORIATIC SPONDYLOARTHRITIS CORRELATES WITH COMPONENTS OF PATIENT FUNCTIONAL STATUS
Authors: T. Kehler, I. Uravić Bursać, V. Drvar, V. Persic, G. Laskarin
Journal: Annals of the Rheumatic Diseases (2022)

Background Activated monocytes represent the main source of pro-inflammatory chemokine, Monocyte Chemoattractant Protein-1 (MCP-1) in psoriatic skin lesions and synovial tissue during active psoriatic arthritis (PsA) (1). Osteoclast precursors binds MCP-1, implying the involvement of MCP-1 in the pathogenesis of bone erosion (2). MCP-1 is present in the plasma of patients with psoriasis at higher levels than in healthy subjects (3). Objectives The aim of this study was to determine the relationship between serum MCP-1 concentration and disease activity in PsA patients. Methods We enrolled 52 patients with PsA in the study and assessed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Functional index (BASFI), and the spread of psoriasis using Body Surface Area (BSA) method. In the serum, C-reactive protein (CRP) was measured using immunoturbidimetric assay and MCP-1 concentration using ELISA. Relationship between two parameters was analyzed applying Spearman correlation and p&lt;0.05 was considered significant. Results Serum MCP-1 concentration did not correlate with the BSA, the DAPSA, CRP, the number of tender joints from 68 evaluated, the number of swollen joints from 66 evaluated, the patient’s assessment of the intensity of pain and overall disease activity during the last week. The concentration of MCP-1 did not correlate with the fatigue, the intensity of pain in axial and peripheral joint structures, the sensitivity to touch, the duration of morning stiffness, BASDAI and BASFI. MCP-1 statistically significantly correlated with the score for getting up from a sitting position without the help of hands, for getting up from a floor without the help, for standing up without supporting for 10 minutes and for performing physically demanding activities (Figure 1). Figure 1. Correlation of serum MCP-1 concentration and BASFI components in patients with PsA. Conclusion Serum MCP-1 concentrations in PsA patients seem to reflect some components of patient functional status. References [1]Furst DE, Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):135. [2]Yao Y, Cai X., Ren F., Ye Y. Et al.Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases.Front Immunol. 2021; 12: 664871. [3]Woo Y R et al. The Risk of Systemic Disease in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic. Int J Mol 2020 (21)7041. Acknowledgements University of Rijeka supported the resarch by the grants Uni-ri-biomed-18-110 and Uni-ri-biomed-18-160. Disclosure of Interests None declared
AB1142 EFFECTS OF SULFASALAZINE USED IN AXIAL SPONDYLOARTHRITIS ON COVID-19 OUTCOMES: REAL-LIFE DATA FROM A SINGLE CENTER
Authors: B. Armagan, E. Atalar, S. C. Güven, B. Özdemir, H. E. Konak, P. Akyüz Dağli, A. Erden, K. Gok, Y. Maraş, I. Dogan, O. Küçükşahin, S. Erten, A. Omma
Journal: Annals of the Rheumatic Diseases (2022)

Background Compared to biologic-agents, little is known about effects of sulfasalazine used for axial spondyloarthritis(AxSpA) on COVID-19 outcomes. Objectives So, we aimed to understand the impact of sulfasalazine on COVID-19 in AxSpA patients. Methods This was a retrospective study from a single center which included 2344 AxSpA patients. We analyzed 219 of 406 confirmed COVID-19 patients from March 2020 to July 2021. The primary outcome was COVID-19 severity in terms of COVID-19 pneumonia, hospitalization rate and length of hospitalization. Analyses were stratified according to use of sulfasalazine and/or biologic-agents. Results Most of the patients were male(59%) with a mean age of 45.0 years. Peripheral arthritis was present in 35% and uveitis in 15%. In total, sulfasalazine was used in 42% and biologic-agent in 42%. COVID-19 pneumonia detected in 16%, hospitalization required in 14% and median(IQR) duration of hospitalization was 10(8) days. Two patients died due to COVID-19. The sulfasalazine users had higher age, more frequent COVID-19 pneumonia, hospitalization and longer hospitalization. After biologic-agent users were excluded, the sulfasalazine group had again longer hospitalization. When patients regrouped as sulfasalazine monotherapy, sulfasalazine+biologic and biologic monotherapy, in pairwise comparisons, sulfasalazine monotherapy group had a higher frequency of COVID-19 pneumonia than biologic monotherapy group(p=0.008). Conclusion Although sulfasalazine seemed to be related with increased rates of COVID-19 pneumonia and hospitalization, this impact diminished after exclusion of biologic-agent users. Sulfasalazine monotherapy and sulfasalazine+biologic therapy might be associated with development of COVID-19 pneumonia, compared to biologic monotherapy. Our results imply sulfasalazine may be related with worse disease course AxSpA patients with COVID-19. Disclosure of Interests None declared
AB1065 EARLIER ONSET OF ARTERIAL HYPERTENSION IS A RISK FACTORS FOR SEVERE COURSES OF GOUT
Authors: E. Markelova, E. Ilinykh, D. Karateev, E. Luchikhina
Journal: Annals of the Rheumatic Diseases (2022)

Background Comorbidities cardiovascular disease such as arterial hypertension (AH) are common in people with gout and complicate its management and disease outcomes. Objectives Our purpose was to evaluate the effect of AH on the severity of gout. Methods We included data of 286 male patients with gout: median (Ме) age 51.2 [interquartile range (IR) 42.8;59.4] years (ys), disease duration – Ме 6.2 [IR 3.8;12.1] ys, number of joints involved during disease course – Ме 7 [IR 4;12], subcutaneous tophi – in 35% pts, intraosseous tophi – in 44% pts. All pts underwent standard clinical examination. AH was defined using by 2018 ESC/ESH Guidelines for the management of arterial hypertension criteria: elevated blood pressure (BP) (systolic BP≥140 or diastolic BP≥90 mm Hg or treatment for hypertension). Results AH was found in 244 out of the 286 pts (85 %). AH was diagnosed before gout in 129 (52.9%) pts, and after gout - in 115 (47.1%) pts. The 1 st degree of AH was found in 27 (11%), the 2 nd degree – in 62 (25%), the 3 rd degree – in 155 (64%) pts. AH developed at a younger age in patients with 3 rd degree AH compared to patients with 2 nd and 3 rd degree AH, but did not reach statistical significance. Patients with 3 rd degree of AH had longer gout and AH duration compared to patients with 1 st and 2 nd degree of AH. They had higher prevalence of subcutaneous and intraosseous tofuses, nephrolithiasis compared with the 1 st and 2 nd degree of AH, p&lt;0.05 (Table 1). Table 1. Parameters Grade 1 hypertension Grade 2 hypertension Grade 3 hypertension Age of gout onset,ys 41.6[34.4; 53.5] 39.6[35.6; 48.0]• 44.1[36.9; 52.6] Age of AH onset,ys 44.9[37.4; 55.4] 43.6[36.9; 49.9] 40.4[29.9; 49.9] Gout duration,ys 3.8[1.6; 5.8] 5.6[3.8; 13.5] 8.0[4.8; 14.6]* AH duration,ys 0.1[0; 2.0] 3.3[0.2; 9.8] 11.3[4.7; 22.8]* Number of joints involved,n 4.0[2.0; 6.0] 7.0[4.0; 10.0] 9,0[5,0; 14.0]* Subcutaneous tophi,% 4(14.8%) 16(26%) 69(44.5%)* Intraosseous tophi,% 5(18.5%) 29(47%) 83(53.5%)* Nephrolithiasis,% 16(59%) 34(55%) 124(80%)* Data are presented in median values and IR (unless otherwise noted), •p&lt;0,05 reliability of differences for trend, *p&lt;0,05 compared vs group 3 (Mann -Whitney). AH preceded the development of gout in 26% pts with 1 st degree of AH, in 42% pts with 2 nd degree of AH, in 62% pts with 3 rd degree of AH. Conclusion Hypertension preceded the development of gout in 62% patients with 3 rd degree of AH. They had a more severe course of gout compared to patients with 1 st and 2 nd degree of AH. It can be assumed that an earlier onset of AH is a risk factor for severe courses of gout. Disclosure of Interests None declared
scDART: integrating unmatched scRNA-seq and scATAC-seq data and learning cross-modality relationship simultaneously
Authors: Ziqi Zhang, Chengkai Yang, Xiuwei Zhang
Journal: Genome biology (2022)

Abstract It is a challenging task to integrate scRNA-seq and scATAC-seq data obtained from different batches. Existing methods tend to use a pre-defined gene activity matrix to convert the scATAC-seq data into scRNA-seq data. The pre-defined gene activity matrix is often of low quality and does not reflect the dataset-specific relationship between the two data modalities. We propose scDART, a deep learning framework that integrates scRNA-seq and scATAC-seq data and learns cross-modalities relationships simultaneously. Specifically, the design of scDART allows it to preserve cell trajectories in continuous cell populations and can be applied to trajectory inference on integrated data.
Characteristics and Outcomes of Patients With COVID-19–Associated ARDS Who Underwent Lung Transplant—Reply
Authors: Adwaiy Manerikar, G. R. Scott Budinger, Ankit Bharat
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0053 LncRNA NUTM2A-AS1 ALLEVIATED OSTEOARTHRITIS BY REGULATING miR-183-5p/TGFA PATHWAY
Authors: N. Geng, D. Yun, D. Liu, P. Liu
Journal: Annals of the Rheumatic Diseases (2022)

Background Osteoarthritis(OA) is a common comorbidity in the elderly, characterized by articular cartilage degeneration, hyperosteogeny and synovitis. Long non-coding RNAs (LncRNAs) have been shown to be involved in several human diseases, including OA. However, the effect of NUTM2A-AS1 on chondrocytes remains unknown. Objectives The purpose of this study was to evaluate the role of LncRNA NUTM2A-AS1 in OA pathological changes in vitro. Methods Chondrocyte cells were treated for 24 hours to mimic OA pathological conditions. The experimental center used chondrocytes with interleukin-1 beta (IL-1β) Intervention to simulate the pathological state of OA.The expression levels of LncRNA NUTM2A-AS1, miR-183-5p and TGFA mRNA were detected by quantitative real-time PCR (qRT-PCR), along with CCK-8 to determine cell viability. Inflammatory response was assessed by determining the release of pro-inflammatory factors such as TNF-α and IL-6 using ELISA kits. Cell apoptosis was examined by flow cytometry assay. The binding relationship between miR-183-5p and LncRNA NUTM2A-AS1 or TGFA was confirmed by dual-luciferase reporter assay. Results IL-1β induced chondrocytes to express LncRNA NUTM2A-AS1 and TGFA, and the miR-183-5p expression was decreased in IL-1β-treated cells. Low expression of LncRNA NUTM2A-AS1 or TGFA mitigated IL-1β-caused chondrocyte viability reduction and apoptosis promotion. miR-183-5p overexpression alleviated IL-1β-mediated chondrocyte apoptosis and inflammatory injury via decreasing TGFA expression. In addition, our work revealed that miR-183-5p is a target of LncRNA NUTM2A-AS1. Rescue experiments showed that TGFA overexpression could reverse the effects of low expression of LncRNA NUTM2A-AS1 on the pathological changes in IL-1β-induced chondrocytes. Conclusion Low expression of LncRNA NUTM2A-AS1 significantly mitigated the chondrocytes damage induced by IL-1β through regulating miR-183-5p/TGFA axis, which might be an important target to regulate the promotion of OA. References [1]Kong H, Sun ML, Zhang XA, Wang XQ. Crosstalk Among circRNA/lncRNA, miRNA, and mRNA in Osteoarthritis[J]. Front Cell Dev Biol, 2021, 9:77437 Disclosure of Interests None declared
AB0871 Factors associated with radiographic hip involvement in ankylosing spondylitis
Authors: G. Mouna, M. Jguirim, N. Benchekaya, S. Zrour, I. Bejia, M. Touzi, N. Bergaoui
Journal: Annals of the Rheumatic Diseases (2022)

Background Hip involvement is a classic feature of ankylosing spondylitis (AS). It causes functional impairement and disability in patients with AS. Although, many studies have looked at factors associated with radiographic hip involvement, these remain debated. Objectives To define the factors associated with radiographic hip involvement in patients with AS. Methods A cross-sectional comparative study of 105 patients was performed. Hip involvement was defined as hip pain considered related to AS inflammation and confirmed radiographically. The patients were classified into two categories: (1) no hip involvement, (2) hip involvement according to a Bath Ankylosing Spondylitis Radiology Index (BASRI)-hip score ≥2. Multivariate logistic regression analyses were used to identify the factors associated with radiographic hip involvement. Results Fifty-three patients had radiological hip involvement and 52 patients were whithout hip involvement. Multivariate logistic regression analyses showed male sex (OR 6.383 IC 1.553-26.29, p=0.010), Bath Ankylosing Spondylitis Functional Index (BASFI) score (OR 1.436, IC 1.079-1.913, p=0.013), and BASRI-spine score (OR 1.456, IC 1.190-1.783, p&lt;0.001) to be significantly associated with radiographic hip involvement, and an inverse relation-ship with age at onset (OR 0.955, IC 0.995-0.998, p=0.038) was seen. Conclusion Male sex, younger age at onset, worse BASFI score and worse BASRI-spine score are associated with radiographic hip involvement. AS patients with risk factors for radiographic hip involvement should be diagnosed at an early stage to improve their quality of life. References [1]Zhao J, Zheng W, Zhang C, Li J, Liu D, Xu W. Radiographic hip involvement in ankylosing spondylitis: factors associated with severe hip diseases. J Rheumatol. 2015 Jan;42(1):106-10. [2]Burki V, Gossec L, Payet J, Durnez A, Elhai M, Fabreguet I, Koumakis E, Meyer M, Paternotte S, Roure F, Dougados M. Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients. Clin Exp Rheumatol. 2012 Jul-Aug;30(4):481-6. Epub 2012 Aug 29. [3]Chen HA, Chen CH, Liao HT, Lin YJ, Chen PC, Chen WS, et al. Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis. Semin Arthritis Rheum 2011;40:552-8. Disclosure of Interests None declared
POS0978 LUMBAR FACET JOINTS ARTHRITIS RELATES TO ITS ADJACENT MRI INFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS
Authors: Z. Huang, L. Huang, X. Guo, Q. Huang, M. Liu, F. Feng, T. LI
Journal: Annals of the Rheumatic Diseases (2022)

Background Facet joints are frequently impaired in patients with axial spondyloarthritis (axSpA), which raises high disease activity and poor physical function. However, insufficient attention is paid to the relationship between the feature of disease and facet joint arthritis (FJA) in magnetic resonance imaging (MRI) examination, because of lacking an ideal assessment tool. The Canada-Denmark (CANDEN) MRI scoring system is adopted in our study because it is a comprehensive method to assess the alteration of spine [1]. Objectives We aimed to find relevant factors for lumbar FJA in axSpA patients. Methods This was a cross-sectional study that analyzed the lumbar MRI of axSpA patients using the CANDEN system. Demographic and clinical information was recorded. Univariate and multivariate linear mixed model (LMM) was used to screen related factors for lumbar FJA in MRI examinations. Results (1) Totally 108 axSpA patients were investigated in our study, while ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) accounted for half respectively. Sixty-five (60.19%) participants were male and their median age was 35 years. (2) Twenty (37.10%) and 1 (1.80%) AS and nr-axSpA suffered lumbar FJA (P&lt;0.05). (3) Univariate LMM found gender, vertebral body corner inflammation subscore (VBCIS), spondylodiscitis subscore (SDS), posterolateral elements inflammation subscore (PLEIS), fat posterior elements subscore (FPES), fat vertebral body subscore (FVBS), and AS disease activity score with C-reactive protein (ASDAS) related to lumbar FJA in AS patients. Besides, gender, the duration of symptom, peripheral arthritis, enthesitis, non-steroidal anti-inflammatory drugs, VCBIS, SDS, PLEIS, FPES, the ankylosis of sacroiliac joints, and bony erosion of hips were involved in the univariate LMM for nr-axSpA. (4) Multivariate LMM displayed that odd ratio (OR) and 95% confidence intervals (CI) of PLEIS, FPES, and ASDAS were 0.66 (0.40, 0.91), 0.45 (0.20, 0.71), and 0.23 (0.01, 0.44) (P&lt;0.05). OR (95%CI) for VBCIS and PLEIS were 0.02 (0.00, 0.04) and 0.23 (0.16, 0.30) in nr-axSpA patients (P&lt;0.05). Conclusion Prevalence of lumbar FJA is higher in AS patients than nr-axSpA. This lesion is mainly related to MRI changes of its neighborhood structure, especially inflammatory alterations, rather than demographic and clinical characteristics. References [1]Krabbe S, Østergaard M, Pedersen SJ, et al. Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis: updated definitions, scoring rules and inter-reader reliability in a multiple reader setting. RMD Open. 2019;5(2):e001057. Disclosure of Interests None declared